Chlorpropamide alcohol flushing (CPAF) in non-insulin-dependent diabetics (NIDDs) has been reported to be associated with a lower tendency to develop late complications. The flush was thought to be mediated by enkephalins and prostaglandins. Early studies could not correlate CPAF to increased levels of acetaldehyde in blood and the flush was not regarded as an antabuse-like reaction.
A well known side effect of chlorpropamide medication in some diabetics is a facial flush after drinking alcohol, even in small amounts. 1 This chlorpropamide alcohol flush (CPAF) is found in many patients with non-insulin-dependent diabetes mellitus (NIDD) and it has been suggested that it is an autosomal dominant inherited trait. 2 The CPAF positive diabetics are reported to have a lower prevalence of diabetic retinopathy 3 as well as macroangiopathy 4 -5 and peripheral neuropathy 5 than the CPAF negative diabetics.
In many patients, however, the presence or absence of flush during a CPAF challenge test is difficult to judge. This has made many investigators uncertain about the prevalence and specificity of the flush. An endogenous opiate, enkephalin, can induce a similar flush and CPAF can be blocked by naloxone. 6 Inhibitors of cyclooxygenase, such as aspirin 7 -8 and indomethacin, 9 reduce the flush in CPAF positive diabetics who are free of vascular complications, suggesting that prostaglandins are also involved.
CPAF was not believed to be an antabuse-like reaction because an investigation by FitzGerald et al. 10 did not find any correlation between blood levels of acetaldehyde and the flush. It was suggested that an antabuse-like reaction should appear in all patients during an alcohol challenge test and would not be an inherited trait. 2 Ethanol is metabolized via acetaldehyde to acetic acid, and the enzymes responsible for these reactions are alcohol dehydrogenase and aldehyde dehydrogenase, respectively. Since chlorpropamide most likely inhibits the aldehyde dehydrogenase, 11 we wanted to study the levels of acetaldehyde during the chlorpropamide alcohol flush.
PATIENTS AND METHODS
Following the method of previous studies, we selected 13 clearly CPAF positive and 13 clearly CPAF negative patients with NIDD. Eight of the flushers and four of the nonflushers were women. The mean age was 69 (59-82) yr in the flushing group and 60 (33-76) yr rn the nonflushing group. The mean duration of diabetes after diagnosis was 8.8 (2-22) yr and 4.7 (1-12) yr, respectively. Four of the CPAF positive diabetics were on diet only, seven were on maintenance therapy with chlorpropamide (two on 125, two on 250, and three on 375 mg daily) and two were on other sulphonylurea drugs. Four of the CPAF negative diabetics were on diet only, three were on chlorpropamide (one on 125 and two on 250 mg daily), and six were on other sulphonylurea drugs. CPAF challenge test. Sixteen of the patients had a standard dose of 250 mg chlorpropamide 12 h before the CPAF test. Three patients had 125 mg, four patients had 250 mg, and three patients had 375 mg in the morning because they were on maintenance therapy with those dosages.
The patients were studied in a room with constant temperature and the skin temperature was measured every 5 min 2 cm below the lateral canthus of the left eye during the test. A sensitive temperature probe from Electrolaboratory (Copenhagen) was used. When the skin temperature vseemed to remain constant (after 20-30 min), the patients had 8 g of pure alcohol in fruit juice. After 30 min, the appearance or absence of flush was judged by us and by the patients themselves. Plasma acetaldhyde and ethanol. Samples for plasma acetaldehyde and ethanol were taken before and 25 min after the alcohol ingestion. Plasma levels of ethanol and acetaldehyde were determined by head space gas chromatography. Acetaldehyde was derivated with semicarbazide by a modification of the method described by Stowell. 12 Blood samples were collected in 10-ml vacuum tubes containing 3 ml buffered semicarbazide solution, prepared fresh for every trial to avoid artifactual formation of acetaldehyde «t (Lindros, personal communication). Blood cells were separated by centrifugation in graded tubes, and 2 ml of the diluted plasma samples thus obtained was transferred to precooled 25-ml glass vials. Seventy percent perchloric acid (0.1 ml) was added to hydrolyze the acetaldehyde semicarbazone. Tert-Butanol was used as internal standard. The glass vials were sealed with a rubber membrane and incuy bated at a temperature of 65°C for 20 min. Five milliliters of the head space was injected in a Varian 2400 gas chromatograph equipped with a flame ionization detector. A Porapak Q column was used, maintained at 110°C. Alcohol challenge test. In three other clearly CPAF positive diabetics, we performed an alcohol challenge test. This was done in the same way as a CPAF challenge test, but without premedication with chlorpropamide. We waited at * least 10 days after the CPAF challenge test before this test was performed. The Student's t test was used for statistical analysis.
RESULTS
As expected, the 13 previously known CPAF positive patients flushed, while the 13 CPAF negative patients did not. A very intense flush was seen in three women, while two flushing men had only a light flush. Of the CPAF negative patients, no one claimed to feel facial warmth and no facial redness was observed. Skin temperature. The two groups (CPAF positive and negative patients) had a starting skin temperature of 32.6 ± 0.3°C and 33.4 ± 0.4°C (mean ± SEM, N.S.), respectively. Thirty minutes after ethanol administration, the increase in skin temperature of the flushers was 2.2 ± 0.4°C (mean ± SEM), while the nonflushing patients had an increase of only 0.6 + 0.2°C (mean ± SEM, P < 0.001). Two of the clearly CPAF patients had an increase less than 1°C, while three of the clearly CPAF negative patients had an increase in facial temperature of 1°C or more (Figure 1 x x x x x x patients had somewhat higher levels (8 and 5 mmol/L, respectively). Plasma acetaldehyde. Baseline levels of plasma acetaldehyde were below or at the detection level. Twenty-five minutes after the ethanol administration, the assays of plasma acetaldhyde showed an increase of 15.0 ± 4.0 fxmoUL in the CPAF positive but only an increase of 2.1 ± 0.2 /imol/L (mean ± SEM) in the CPAF negative patients (P < 0.005). This increase was greater in all of the flushers than in any of the nonflushers. In 8 of the 13 flushers, there was a considerable increase ( Figure 2) . Alcohol challenge test. The mean skin temperature increase was reduced from 3.7°C (range 3.0-5.1°C) at the CPAF challenge tests to 1.2°C (range 0.7-1.7°C) at the alcohol challenge tests. Plasma ethanol levels were the same in all three patients at both challenge tests but the mean increase of plasma acetaldehyde was reduced from 13.3 /xmol/L (range 6-26) to 3.7 ju,mol/L (range 3-4).
DISCUSSION
Plasma acetaldehyde is elevated during the chlorpropamide alcohol flush and, as acetaldehyde is the first product in the metabolism of ethanol, this would be the first metabolic step of the flush. 13 There are many problems with skin temperature registrations. Two of the 13 clearly flushing patients had an increase less than 1°C during the flush. In one patient, the explanation was that the flush was localized to the nose and did not reach the point where the skin thermometer probe was attached. In 3 of the 13 nonflushers, the increase in skin temperature was more than 1°C. This could be due to a lack of stability in the starting temperature. Emotional stress caused by the blood sampling procedure is another possible explanation.
The plasma ethanol concentrations were very low, as expected after the administration of only 8 g of ethanol. Although there was no significant difference in mean plasma ethanol concentrations between the two groups, two flushers had somewhat higher levels. One also had a high plasma acetaldehyde concentration during the flush, but the other only had a moderately elevated acetaldehyde concentration. Furthermore, the flushing patient with the highest acetaldehyde level during the flush had a very low ethanol concentration.
Higher ethanol concentrations might have influenced the acetaldehyde levels in two ways: (1) by increased oxidation of ethanol to acetaldehyde in vivo and (2) by increased artifactual formation of acetaldehyde during sample processing. However, our own studies on ethanol metabolism suggest that these mechanisms account for less than 1 /ifnol/L of the observed difference in plasma acetaldehyde.
In 1962, FitzGerald et al. 10 investigated four patients by measuring blood acetaldehyde during a chlorpropamide alcohol flush. They could not find any differences following ethanol ingestion with or without chlorpropamide treatment. Acetaldehyde was determined on whole blood samples by Stotz's method after distillation into bisulphite, and ethanol was determined by the method of Kent-Jones and Taylor. When acetaldehyde concentrations in the range of those found during CPAF challenge tests are analyzed, these methods are not regarded as sensitive enough.
Similar results were reported by Buttner in 1961. 14 He studied alcohol intolerance after tolbutamide. The patients were given a maximal dose of tolbutamide (3 g daily), and on the third day, ethanol was given in large quantities (0.5 g per kg body wt). Plasma acetaldehyde concentrations were determined by a spectrophotometer after an enzymatic analysis. All 12 of the tested patients flushed and all had an increase of acetaldehyde. This increase was correlated to the intensity of the flush. Although ethanol ingestion was 4 -6 times greater and tolbutamide was given in a very large dose, our results confirm Buttner's work.
In 1968, Podgainy and Bressler suggested that chlorpropamide inhibits the aldehyde dehydrogenase, but a correlation between the flush and acetaldehyde was not studied. In this study, we have shown that 13 flushing patients had significantly higher plasma acetaldehyde levels than any of 13 nonflushing patients during a CPAF challenge test. Like Buttner, 14 we were able to anticipate the acetaldehyde levels in those with marked flushes. The two highest plasma acetaldehyde levels (35 and 53 /umol/L) are in the same range as those found in a mild antabuse reaction. When CPAF positive patients are exposed to alcohol without premedication with chlorpropamide, a reduction of plasma acetaldehyde concentrations to the levels of the CPAF negative patients was found, suggesting an inhibitory effect of chlorpropamide on aldehyde dehydrogenase.
In one CPAF positive patient, the administration of naproxene, a prostaglandin synthesis inhibitor, did not abolish the increase of acetaldehyde, although there was no flush at all. In two other patients, the administration of aspirin reduced the flush without reducing the increase of acetaldehyde. This speaks in favor of a more complicated relation between acetaldehyde and the flush. As suggested by others, prostaglandins are probably involved.
The significant increase of acetaldehyde after ethanol ingestion in the CPAF positive patients could be caused by a lower activity of aldehyde dehydrogenase or by a more efficient chlorpropamide-induced inhibition of the aldehyde dehydrogenase. Indeed, our studies show significantly higher levels of chlorpropamide in the flushers. 15 Thus, heriditary factors in the pharmacokinetics of sulfonylurea might possibly be related to the reported genetic'differences between CPAF positive and negative diabetics.
In conclusion, we have demonstrated that the chlorpropamide alcohol flush is correlated to a rise of plasma acetaldehyde levels. The acetaldehyde measurement appears superior to skin temperature measurement in providing an objective method to study CPAF.
